Susquehanna International Group, LLP Galera Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	SELL	$2.5 - $3.42 $396,000 - $541,728	-158,400 Reduced 79.4%	41,100 $128,000
Q1 2023 May 16, 2023	BUY	$1.48 - $2.68 $269,804 - $488,564	182,300 Added 1059.88%	199,500 $510,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.76 $5,494 - $7,216	-4,100 Reduced 19.25%	17,200 $25,000
Q3 2022 Nov 14, 2022	BUY	$1.15 - $2.1 $919 - $1,680	800 Added 3.9%	21,300 $37,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $335,544 - $646,734	-270,600 Reduced 92.96%	20,500 $27,000

Q1 2022 May 16, 2022	SELL	$2.01 - $4.19 $246,224 - $513,275	-122,500 Reduced 29.62%	291,100 $693,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $8.28 $525,272 - $3.42 Million	413,600 New	413,600 $1.9 Million

10.7M

10.3K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $3.76M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.